Identification of Etiopathological and Clinical Factors in Persistent Genital Arousal Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2023-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of (possible etiological) factors associated with PGAD symptomatology as well as description of comorbid disorders subjects with PGAD.

Persistent genital arousal disorder (PGAD) is a presumably rare, although debilitating condition, which was first defined at the beginning of this century and has not yet found consideration by any of the international classification systems of diseases. PGAD is commonly characterized by persistent and unwanted sensations of genital arousal which are not related to subjective feelings of sexual desire or arousal. Affected patients which are predominantly women can suffer tremendously. The lack of basic research on the etiology of PGAD leads to insufficient therapeutical approaches.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Female Sexual Dysfunction: Prevalence Among Italian Healthy Women

NCT00148200

Sexual Dysfunctions, Psychological

COMPLETED

Observational Study on Metabolism and Psychopathology in Transsexual Patients

NCT02185274

Transsexualism

COMPLETED

Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women

NCT01977313

Libido Receptors, Androgen Polymorphism, Genetic +1 more

COMPLETED

Testosterone in Female Hypoactive Sexual Desire Disorder

NCT00140153

Hypoactive Sexual Desire Disorder

COMPLETED PHASE3

Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones

NCT00447512

Healthy Major Depression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The entire approach is of multimodal and explorative nature as only very limited information on this disease is available so far (hypotheses generating). Moreover, the aim of the study is to characterize PGAD patients in terms of their biography (e.g. trauma), comorbidities and life quality.

Clinical assessment:

* Psychological/psychiatric examination
* Neurological examination
* Gynecological/urological examination
* Laboratory assessment
* Structural and Functional Magnetic Resonance Imaging

General Hypotheses:

1. There is a morphological correlate of PGAD that affects or represents a neuronal structure leading to altered perception of genital sensation (e.g. Tarlov cysts, varices, …).
2. There is a functional correlate of PGAD in the central nervous system (CNS) indicating a hyperfunction (excitation or disinhibition) or hypofunction (inhibition) of specific brain areas including hypothalamus, sensory cortex of the genitals and secondary brain areas, brain stem centers (e.g. raphe nuclei) and others.
3. Patients with PGAD show an elevated rate of previous pharmacological treatment with drugs that may alter the central processing of sexual/genital perception or reveal a specific pattern of comorbid diseases (e.g. affective or somatoform disorders) that may predispose other disorders such as PGAD, pain disorders etc.

Expected results and exploitation:

The proposed project will help to identify clinical and neurobiological correlates of persistent genital arousal (PGAD) and will provide

1. a deeper clinical, (neuro)psychological and (neuro)biological understanding of PGAD
2. help to identify related etiopathological mechanisms of PGAD
3. inform clinicians and (sex) therapists on diagnostic issues and promising treatment targets in PGAD derived from comprehensive clinical and experimental measures
4. stimulate further neurobiological and clinical research in the field of PGAD, leading to further national and international cooperation and applications
5. a considerable number of publications in leading scientific journals and raise awareness of a rare disease not only among all clinicians dealing with sexual problems but also general practitioners and others.

Objective(s):

Investigation of (possible etiological) factors associated with PGAD symptomatology as well as description of comorbid disorders subjects with PGAD.

Statistical Analysis:

Clinical (psychological, neurological and gynecological/urological) data is analyzed using a descriptive approach of frequencies and mean values of diverse clinical findings as well as a group comparison (patients versus healthy controls) using respective statistical analyses such as ttests, chi-square test and others after having tested for normal distribution where necessary. MRT data is analyzed using state-of-the-art special software (SPM) including group comparisons.

Sample Size Justification:

This is a cross-sectional study of a rare disease. At MHH usually 10 new patients occur per year. The investigator tries to include as many patients as possible and will probably achieve higher numbers by advertising the study and using data banks of already existing cases. Due to the presumably rare number of people affected with PGAD and the very few existing publications which are mostly case reports and the even fewer PGAD related MRI data a statistically neat sample size computing is not simple. The investigator cannot refer to prior carried out PGAD related MRI studies and to publications mentioning PGAD sample sizes. However, for MRI studies methodological work investigating the reliability of statistical effect in fMRI studies exist. An article by Thirion in 2007 shows that a sample size between 20 and 30 subjects per group is sufficient to detect statistical effects. This is also in accordance with common practice in fMRI aiming at at least 20 subject per group at which results become quite stable (Murphy \& Garavan 2004) Thus, the investigator aims at a sample size of 25 subjects per group. To account for potential dropouts (\~10%, mainly due to excessive head movement in the MRI scanner) it is planned to include approximately 30 subjects per group.

Discussion of Perceived / Expected Risks and Benefits:

When considering all exclusion criteria for MRI there are no risks known for using a magnetic resonance imaging system. Clinical and (neuro)psychological testing might be perceived stressful by some participants and therefore may lead to a temporary increase in blood pressure and/or heart rate that will normally end after testing. Clinical examination (neurological and gynecological/urological) might lead to discomfort in some participants. Besides the neurological examination which can result in uncomfortable feelings (e.g. minor pain) during the ENoG-testing and Pudendus-SEP and that will normally end immediately after testing the clinical examination is pain-free. Blood Sampling might be painful and lead to hematoma. The amount of blood is low (approx. 30ml). Any serious damage to the organism during clinical examination and blood sampling is very unlikely.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Genital Syndrome Sexual Arousal Disorder Orgasmic Disorder Psychosexual Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women and men fulfilling PGAD-criteria

Inclusion criteria:

\- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum \& Nathan (2001).

Exclusion criteria:

\- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.

Age:

\- 18 - 65 years of age

Gender:

\- Female and male subjects